Personal information

No personal information available

Activities

Employment (1)

food and drug administration: silver spring, TW

2004-09-15 to present
Employment
Source: Self-asserted source
yuan-li shen

Education and qualifications (1)

University of North Carolina at Chapel Hill: Chapel Hill, NC, US

1987-08-26 to 1993-01-10 | Dr. P.H. (Biostatistics)
Education
Source: Self-asserted source
yuan-li shen

Works (10)

FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma

Clinical Cancer Research
2024-01-17 | Journal article
Contributors: Timil H. Patel; Jamie R. Brewer; Jiaxin Fan; Joyce Cheng; Yuan-Li Shen; Yue Xiang; Hong Zhao; Steven J. Lemery; Richard Pazdur; Paul G. Kluetz et al.
Source: check_circle
Crossref

Data from FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum

2024-01-05 | Preprint
Contributors: Sonia Singh; Diana Bradford; Xiaoxue Li; Pallavi S. Mishra-Kalyani; Yuan-Li Shen; Lingshan Wang; Hong Zhao; Ye Xiong; Jiang Liu; Rosane Charlab et al.
Source: check_circle
Crossref

Data from FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum

2024-01-05 | Preprint
Contributors: Sonia Singh; Diana Bradford; Xiaoxue Li; Pallavi S. Mishra-Kalyani; Yuan-Li Shen; Lingshan Wang; Hong Zhao; Ye Xiong; Jiang Liu; Rosane Charlab et al.
Source: check_circle
Crossref

FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum

Clinical Cancer Research
2024-01-05 | Journal article
Contributors: Sonia Singh; Diana Bradford; Xiaoxue Li; Pallavi S. Mishra-Kalyani; Yuan-Li Shen; Lingshan Wang; Hong Zhao; Ye Xiong; Jiang Liu; Rosane Charlab et al.
Source: check_circle
Crossref

Supplementary Table S1 from FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum

2024-01-05 | Preprint
Contributors: Sonia Singh; Diana Bradford; Xiaoxue Li; Pallavi S. Mishra-Kalyani; Yuan-Li Shen; Lingshan Wang; Hong Zhao; Ye Xiong; Jiang Liu; Rosane Charlab et al.
Source: check_circle
Crossref

Supplementary Table S1 from FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum

2024-01-05 | Preprint
Contributors: Sonia Singh; Diana Bradford; Xiaoxue Li; Pallavi S. Mishra-Kalyani; Yuan-Li Shen; Lingshan Wang; Hong Zhao; Ye Xiong; Jiang Liu; Rosane Charlab et al.
Source: check_circle
Crossref

Supplementary Table S2 from FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum

2024-01-05 | Preprint
Contributors: Sonia Singh; Diana Bradford; Xiaoxue Li; Pallavi S. Mishra-Kalyani; Yuan-Li Shen; Lingshan Wang; Hong Zhao; Ye Xiong; Jiang Liu; Rosane Charlab et al.
Source: check_circle
Crossref

Supplementary Table S2 from FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum

2024-01-05 | Preprint
Contributors: Sonia Singh; Diana Bradford; Xiaoxue Li; Pallavi S. Mishra-Kalyani; Yuan-Li Shen; Lingshan Wang; Hong Zhao; Ye Xiong; Jiang Liu; Rosane Charlab et al.
Source: check_circle
Crossref

FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal Cancer

Clinical Cancer Research
2023-11-01 | Journal article
Contributors: Sandra J. Casak; M. Naomi Horiba; Mengdie Yuan; Joyce Cheng; Steven J. Lemery; Yuan Li Shen; Wentao Fu; Jason N. Moore; Yangbing Li; Youwei Bi et al.
Source: check_circle
Crossref

FDA Approval Summary: Mobocertinib for Metastatic Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Clinical Cancer Research
2023-02-01 | Journal article
Contributors: Elizabeth S. Duke; Liza Stapleford; Nicole Drezner; Anup K. Amatya; Pallavi S. Mishra-Kalyani; Yuan-Li Shen; Kimberly Maxfield; Jeanne Fourie Zirkelbach; Youwei Bi; Jiang Liu et al.
Source: check_circle
Crossref